Visen Pharmaceuticals
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Visen Pharmaceuticals
Chinook Is Advancing Kidney Disease Goals With Surrogate Endpoints, Asian JV
Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.
Ascendis Will Take On Daily Genotropin With Weekly Skytrofa
Ascendis’s growth hormone deficiency drug Skytrofa will offer a convenience advantage as a weekly injectable. But the label does not clearly delineate superiority shown in a Phase III trial.
Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Deals In Depth: November 2015
Sanofi pushed ahead to advance its leadership in diabetes in a partnership with Hanmi; Pfizer bought Allergan in biopharma's biggest M&A to date, at $160bn. Boston Pharma's $600m financing contributed greatly to the early-stage venture category's 50% share of total financing.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule